Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Eli Lilly's $2.875 billion Merida Biosciences deal expands its immunology pipeline, as strong GLP-1 growth continues while LLY shares trail the broader health care sector.
Jacó, Puntarenas - September 01, 2026 - Peptides Costa Rica has introduced a new transparency standard designed to give researchers and buyers clearer access to product verification information, a move...
Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that mos...
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline...
Eli Lilly trades at $1,175 per share and has stayed right on track with the overall market, gaining 15.4% over the last six months. At the same time, the S&P...
Veeva Systems (NYSE:VEEV) reported fiscal 2027 second-quarter revenue of $928 million and non-GAAP operating income of $416 million, with Chief Executive Officer Peter Gassner saying results exceeded the company’s guidance. Management highlighted record CRM performance, broad commercial-cloud moment
August 26, 2026 — Drug discovery can begin with 5,000 to 10,000 compounds, narrow to approximately 250 entering preclinical development , around five reaching clinical trials and ultimately produce just one approved medicine —highlighting why identifying weak drug candidates earlier can be critical to pharmaceutical R&D.
August 26, 2026 — Investor attention is building around several lower-priced small-cap stocks trading near the $0.30 range, including VivoSim Labs, Inc. (NASDAQ: VIVS), IGC Pharma, Inc. (NYSE: IGC), Algorhythm Holdings, Inc. (NASDAQ: RIME) and Xiao-I Corporation (NASDAQ: AIXI), as company-specific catalysts across AI, biotechnology, drug development and logistics technology drive trading interest.VivoSim Labs (NASDAQ: VIVS) — AI Drug Toxicity and FDA NAM Momentum
Eli Lilly looks like a strong long-term investment thanks to its booming obesity drugs and Alzheimer's treatment, and to Billionaire Ken Griffin's investment.
VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.
